Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16646919 | 0.89 | KRAS (0.59) | KRAS | |
| SCHEMBL29765737 | 0.89 | KRAS (0.59) | KRAS | |
| SCHEMBL21937649 | 0.83 | KRAS (0.55) | KRAS | |
| SCHEMBL16646870 | 0.83 | KRAS (0.55) | KRAS | |
| SCHEMBL22029262 | 0.81 | KRAS (0.63) | KRAS | |
| SCHEMBL16646989 | 0.80 | KRAS (0.56) | KRAS | |
| SCHEMBL16637102 | 0.79 | KRAS (0.55) | KRAS | |
| SCHEMBL29765793 | 0.79 | KRAS (0.55) | KRAS | |
| SCHEMBL16646949 | 0.79 | KRAS (0.64) | KRAS | |
| SCHEMBL29766012 | 0.79 | KRAS (0.64) | KRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | KRAS 1/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KRAS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.